"Designing Growth Strategies is in our DNA"

Blood Glucose Monitoring System Market Size, Share & COVID-19 Impact Analysis, By Device Type (Continuous Glucose Monitoring (CGM) Systems and Self-Monitoring Blood Glucose (SMBG) Systems), By Modality (Wearable and Non-wearable), By Type (Non-invasive and Invasive), By Patient Type (Type 1 Diabetes and Type 2 Diabetes), By Distribution Channel (Retail Sales and Institutional Sales), and Regional Forecast 2023-2030

Region : Global | Format: PDF | Report ID: FBI100648

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

Global Blood Glucose Monitoring System market size was valued at USD 15.80 billion in 2022 and is projected to reach USD 32.99 billion by 2030, exhibiting a CAGR of 9.9% during the forecast period. Blood Glucose Monitoring System are used by individuals to measure the glucose levels in blood. These devices are crucial for patients suffering from type 1 and type 2 diabetes. The growing prevalence of diabetes among general population globally is one of the major factors contributing to the rising demand for Blood Glucose Monitoring System.



  • According to the estimations of the International Diabetes Federation (IDF), in 2021, around 537 million adults had diabetes and it is projected to reach around 783 million by 2045. With the increasing prevalence of diabetic patients globally, it is critical for patients to regularly monitor their blood glucose levels to avoid an incidence of hyperglycemia or hypoglycemia.


The adoption of these systems is growing at a faster pace owing to factors such as the increasing patient pool living with diabetes, rising awareness regarding blood sugar monitoring among patients, and the introduction of novel monitoring devices by key players.


Additionally, supportive reimbursement policies for self-monitoring blood glucose (SMBG) and Continuous Glucose Monitoring (CGM) systems in many countries, is another important factor anticipated to boost the adoption of Blood Glucose Monitoring System further and will subsequently propel the market growth during the forecast period.


COVID-19 IMPACT:


Urgency to Expand the Availability of CGM in Hospitals amid COVID-19 Pandemic to Boost Market Growth


The COVID-19 pandemic positively impacted the Blood Glucose Monitoring System market growth. Several key players reported growth in their diabetes care revenue due to the outbreak of the pandemic. With the increasing risk of COVID-19 infection among diabetic patients, a new focus is being placed on home use monitoring devices to manage blood glucose levels at home.



  • For instance, in December 2020, Abbott’s diabetes segment reported a growth of 29.4% as compared to the previous year. The growth was led by its glucose monitoring device that is FreeStyle Libre, with 3.0 million users globally.


Additionally, the COVID-19 pandemic brought new urgency to assess the feasibility of CGM in hospitals in order to monitor patients with diabetes continuously and to limit healthcare professionals’ exposure. Due to this increased demand, in April 2020, the U.S. FDA issued guidance to expand the availability of remote monitoring devices, including CGMs, across healthcare settings in the U.S.


Therefore, as a result of the pandemic, the demand for Blood Glucose Monitoring System especially at home increased and major market players experienced a significant increase in the revenue from these devices post-pandemic as compared to the previous year.



  • For instance, F. Hoffmann-La Roche Ltd., a global leader in diagnostics, generated a revenue of USD 1.69 billion in the diabetes care segment in 2021 and exhibited a growth of 1.2% compared to the previous year.


LATEST TRENDS


Request a Free sample to learn more about this report.


Increasing Penetration of CGM Devices across Various Segments to Augment Growth


The introduction of advanced technologies, such as Continuous Blood Glucose Monitoring (CGM) systems by market players, has enabled the real-time monitoring feature for insulin-dependent patients. Also, CGM systems offer several advantages when compared to Self-Monitoring Blood Glucose (SMBG) systems such as being minimally invasive in nature, less painful, real-time monitoring, and rapid & precise results. Thus, such distinct benefits these devices offer are one of the major factors shifting the preference of healthcare providers and patients toward the use of CGM.



  • For instance, according to the data published by Abbott, the number of FreeStyle Libre users globally increased from 3.0 million in 2020 to 4.0 million in 2021.


Additionally, at present, only a few companies are emphasizing the research and development of non-invasive CGM systems and have introduced a few devices in the Europe market. Thus, the increasing penetration of CGM and the shifting focus of market players toward non-invasive Blood Glucose Monitoring System are some of the major trends observed in this market.


DRIVING FACTORS


Rising Prevalence of Diabetes to Surge the Demand for Blood Glucose Monitoring Devices


Several factors, including rapid urbanization and the rising shift toward a sedentary lifestyle, in emerging and developed countries are primarily responsible for the growing prevalence of diabetes. For instance, according to the data published by the International Diabetes Federation in 2021, it was estimated that around 537 million adults were suffering from diabetes and countries such as China, India, U.S., Brazil, and Mexico accounted for an estimated 51.6% of the global diabetes population in 2021.


A significant increase has been observed in the number of patients suffering from type-1 or insulin-dependent type 2 diabetes, which has been instrumental in surging the uptake of these systems globally. For instance, according to the data published by International Diabetes Federation, in 2021, it was estimated that the incidence of type 1 diabetes was 149.5 per 1,000 in children and adolescents of age (0-19) years and the global prevalence was around 9.8% among the total population.


Thus, the presence of a large diabetic population suffering from insulin-dependent diabetes, new product introduction by market players, and favorable reimbursement are fueling the demand and adoption of diabetes monitoring products such as BGMs. As a result, the market is estimated to grow from 2023-2030.


RESTRAINING FACTORS


Lower Diagnosis & Treatment Rate in Emerging Countries to Restrict the Adoption of BGM 


The presence of a large proportion of the undiagnosed diabetes population is one of the major factors resulting in the lower adoption of Blood Glucose Monitoring System, especially in emerging countries. The prevalence of delayed analysis is higher among countries such as China, India, South Africa, Brazil, and others, in comparison with developed countries. Also, due to the lack of awareness among the general population regarding chronic diseases such as diabetes mellitus. Also, the limited access to advanced healthcare infrastructure and the lack of conventional procedures by government or private organizations may hinder growth.



  • For instance, according to the data published by International Diabetes Federation in 2021, it was observed that in Africa, almost 1 in 2 diabetes patients remain undiagnosed, and in Asia Pacific, the proportion of undiagnosed diabetes population is around 55.0%, mainly driven by countries, such as India, China, and Indonesia.


Thus, all the above factors, along with the lack of refund plans for CGM & SMBG systems, are mainly accountable for the lower diagnosis and treatment rates and would subsequently limit the implementation of these systems in developing countries.


SEGMENTATION


By Device Type Analysis


To know how our report can help streamline your business, Speak to Analyst


Continuous Glucose Monitoring Systems Segment to Grow at a Faster Pace during 2022-2029


The Continuous Glucose Monitoring (CGM) systems segment is anticipated to register a higher CAGR during the forecast period. The significant growth of this segment is attributed to the increasing adoption of CGMs in developed and emerging countries due to their ability to monitor a patient’s blood glucose levels regularly.



  • For instance, according to an article published by John Wiley & Sons, Inc., in 2021, it was observed that due to its ease of use, faster results, and minimally invasive process, CGM devices were found to be more successful than SMBG in controlling type 1 diabetes.


On the other hand, the Self-Monitoring Blood Glucose (SMBG) systems segment dominated the market in 2022. However, the segment is expected to lose its market share by the end of the forecast period due to the high cost of devices, consumables, and growing penetration of CGM devices globally.



  • For instance, according to the data published by Clinton Health Access Initiative Inc., in 2021, it was estimated that if a person uses four test strips per day, the cost of testing strips is projected to be around USD 87.6 and USD 1,285.0 per year.


By Modality Analysis


Wearable Segment to Register Higher CAGR due to Robust Pipeline of Market Players


On the basis of modality, the market includes wearable and non-wearable. The wearable segment is expected to grow at a comparatively higher CAGR during the forecast period due to the increasing number of product launches of wearable CGM devices by domestic and global manufacturers.



  • For instance, in 2021, Know Labs introduced the UBand wristband to continuously monitor blood glucose levels, making it ideal for diabetic patients who need to check their sugar levels on a regular basis.


The non-wearable segment stood at dominating position in the market in 2022. The presence of a large number of market players with robust portfolios of non-wearable systems is one of the major factors responsible for the dominance of this segment.


This, along with the constant focus of players to introduce wearable SMBG devices in the market by the end of the forecast period, is expected to propel the growth of this segment.


By Type Analysis


New Product Launches Led to Higher CAGR of Non-invasive Glucose Monitoring Systems


Due to the pain associated with finger pricking in invasive monitoring devices, key players are now focusing on introducing a non-invasive alternative in the market to improve patient adherence. Thus, the non-invasive segment is expected to grow at a significant rate during the forecast period



  • For instance, in January 2022, a British-based company Scanbo developed a prototype that measures glucose with a 60-second non-invasive finger test rather than a standard blood drop. Thus, the introduction of such convenient alternatives is expected to increase the shift of patients from invasive to non-invasive devices.


Among type, the invasive segment held a dominating share of the global market in 2022. At present, the higher use of SMBG devices among diabetic patients is one of the major factors primarily responsible for the dominance of the invasive segment.


By Patient Type Analysis


Rising Prevalence of Type 2 Diabetes Responsible for the Segmental Dominance


On the basis of patient type, the market is segmented into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment dominated the global market share in 2022, led by the comparatively larger patient population with insulin-dependent type 2 diabetes.



  • For instance, according to the estimates of the International Diabetes Federation (IDF), around 537 million individuals globally were living with type 2 diabetes in 2021, and among these, 1 in 10 of the patient population are at risk of developing type 2 diabetes.


Besides, the type 1 diabetes segment is slated to record a notable CAGR due to the increasing use of Continuous Glucose Monitoring (CGM) systems, owing to its clinically proven efficiency in reducing risks of hypoglycemia in type 1 diabetes patients.


By Distribution Channel Analysis


Preference of Retail Channels by Market Players Boosted the Retail Sales Segment


Based on distribution channel, the market includes institutional sales and retail sales. The retail sales segment captured a substantial market share during 2022 due to increasing initiatives by market players to expand their presence through retail channels in emerging as well as developed countries to strengthen their positions.



  • In March 2021, Omron Healthcare, Inc. announced its plan to expand its retail presence across India. The main aim of the company is to increase the number of retailers in India from 30.0% to 40.0% in the financial year 2021-22.


The institutional sales segment is anticipated to register a comparatively moderate CAGR owing to the lower adoption rate of blood glucose meters in hospitals & clinics. However, due to the outbreak of COVID-19, various medical organizations have recommended expanding access of CGM in hospitals, which is expected to drive the growth of the institutional sales segment during the forecast period.


REGIONAL INSIGHTS


North America Blood Glucose Monitoring System Market Size, 2022 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample


North America dominates the Blood Glucose Monitoring System market share and was valued at USD 6.92 billion in 2022. The increasing number of diabetes patients, growing adoption of technologically advanced medical devices and developed per capita medical expenses are some of the key factors principally accountable for the dominant share of regional market.



  • As per data published by the International Diabetes Federation, it was estimated that around 32.2 million people in the U.S. suffered from diabetes in 2021.


The Europe market is estimated to progress at a healthy CAGR, owing to the increasing awareness among people regarding diabetes management, along with the rapidly increasing demand for these monitoring system for the regular monitoring of patients at home.



  • For Instance, in December 2020, Nemaura, a U.K.-based company, launched ProBEAT, a non-invasive glucose monitoring patch to provide users with feedback and insights into factors that affect blood glucose levels.


Asia Pacific is anticipated to register a substantial CAGR due to the rising prevalence of insulin-dependent diabetes and an increasing geriatric population in this region. Also, diabetic patients in countries, such as Japan and Australia, are actively interested in the regular and timely monitoring of their glucose levels. This, along with the increasing emphasis of key players to develop their direct presence in developing countries.


The Middle East & Africa and Latin America are expected to register a moderate CAGR during the forecast period. This is due to the lack of awareness among the general population regarding diabetes care and inadequate reimbursement policies for Blood Glucose Monitoring System.


KEY INDUSTRY PLAYERS


Diverse Product Portfolio of Major Players to Lead to their Dominance in the Market


The global market is consolidated, with few Blood Glucose Monitoring System players accounting for the largest share in terms of self-monitoring blood glucose systems and few players dominating the field of CGM systems. In 2022, F. Hoffmann-La Roche Ltd., Abbott, and Dexcom, Inc., accounted for the global market.


The strong portfolio of self-monitoring blood glucose SMBG and continuous glucose monitoring CGM systems, coupled with the wide distribution network in developed and emerging countries, are primarily responsible for the dominance of these companies globally.


On the other hand, new entrants are currently focusing on introducing novel non-invasive blood glucose monitors to establish their foothold globally.



  • In April 2021, DiaMonTech AG, a Germany-based company, received the official QMS certification for the design and development of its patented non-invasive “no prick” photothermal detection technology.


Some other notable names in the industry are Medtronic, B. Braun Melsungen AG, Ascensia Diabetes Care Holdings AG, Terumo Corporation, LifeScan IP Holdings, LLC, and Senseonics.


LIST OF KEY COMPANIES PROFILED:



KEY INDUSTRY DEVELOPMENTS:



  • March 2023 – Abbott received the U.S. FDA approval for its FreeStyle Libre 2 and FreeStyle Libre 3 integrated CGM sensors for integration with automated insulin delivery systems.

  • February 2023 – Dexcom, Inc. received the U.S. CMS approval for coverage for its G7 CGM system.

  • September 2022 – Nemaura Medical Inc. partnered with Eversana for the introduction of Nemaura’s diabetes management system in the U.S.

  • August 2022 - Abbott partnered with WW International Inc. to integrate WW International Inc.’s diabetes-tailored weight management program with Abbott’s FreeStyle Libre product portfolio.

  • December 2021 - Nemaura Medical Inc. launched its non-invasive product, SugarBeat, in the U.K. with CE mark approval.


REPORT COVERAGE


An Infographic Representation of Blood Glucose Monitoring Market

To get information on various segments, share your queries with us



The market research report provides a detailed analysis of the industry and focuses on key aspects such as leading companies, device type, modality, patient type, and distribution channels. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the factors mentioned above, the report encompasses several factors focusing on the market forecast that have contributed to the growth of the market in recent years.


Report Scope & Segmentation


































































  ATTRIBUTE



  DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 9.9% from 2023 to 2030



Unit



Value (USD billion)



Segmentation



By Device Type, Type, Modality, Patient Type, Distribution Channel, and Region



By Device Type




  • Continuous Glucose Monitoring Systems

  • Self-Monitoring Blood Glucose Systems



By Type




  • Non-invasive

  • Invasive



By Modality




  • Wearable

  • Non-wearable



By Patient Type




  • Type-1 Diabetes

  • Type-2 Diabetes



By Distribution Channel




  • Institutional Sales

  • Retail Sales



By Geography




  • North America (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel, and By Country)

    • U.S. (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • Canada (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)



  • Europe (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel, and By Country)

    • U.K. (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • Germany (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • France (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • Italy (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • Spain (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • Rest of Europe



  • Asia Pacific (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel, and By Country)

    • China (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • Japan (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • India (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • Australia (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • Korea (By Device Type, By Modality, By Type, By Patient Type, By Distribution Channel)

    • Rest of Asia Pacific



  • Rest of the World (By Device Type, By Modality, By Type, By Patient Type, and By Distribution Channel)



 


Frequently Asked Questions

Fortune Business Insights says that the global market stood at USD 15.80 billion in 2022 and is projected to reach USD 32.99 billion by 2030.

The market will exhibit steady growth at a CAGR of 9.9% during the forecast period (2023-2030).s

Based on device type, the Self-Monitoring Blood Glucose (SMBG) systems segment will lead the market.

The rising prevalence of diabetes wounds and the introduction of advanced products for monitoring blood glucose levels are the key drivers of the market.

F. Hoffmann-La Roche Ltd., Abbott, and Dexcom, Inc. are the top players in the market.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • May, 2023
  • 2022
  • 2019-2021
  • 222

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $6850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- UGlobal hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X